SPEAKERS

Dr Raj Patel (UK)
President- IUSTI, Genito Urinary Medicine, The Royal South Hants Hospital, England.

Professor Ian Frazer (Australia)
CEO and Research Director, Translational Research Institute, QLD, Australia.

Speaker Bios

Dr Sevgi Aral
Sevgi Okten Aral, MA, MS, PhD has been the Associate Director for Science in the Division of STD Prevention, Centers for Disease Control since 1993.  She holds Professorial appointments at the University Of Washington in Seattle; University of Manitoba in Winnipeg and Emory University in Atlanta.

Dr. Aral has authored more than 230 scientific articles and edited 16 journal issues and 2 books.  Dr. Aral has served on many national and international work groups, boards and committees; and has consulted for the World Health Organization, The European Union and the World Bank.  She has received the ASTDA Achievement Award and the Thomas Parran Award.

Over the years, her research interests have included social and behavioral aspects of sexually transmitted disease epidemiology and prevention; including gender, age and race effects; mixing patterns; sexual and social networks; contextual factors; social determinants and most recently, program science.

Dr. Aral came to the Centers for Disease Control from Middle East Technical University in Ankara, Turkey where she was the chair of the Department of Social Sciences.

Associate Professor Roy Chan
Roy is a dermato-venereologist, he is Director of the National Skin Centre and Chairman of the Dermatology Specialist Training Committee in Singapore.

He is the Regional Director of the IUSTI Asia Pacific Branch, Past President of ASAP, and a member of the Governing Council of the IAS. 

Professor King Holmes
Dr. King Holmes became the first William H. Foege Chair of Global Health at the University of Washington effective November 1, 2006, and also is Professor of Global Health, Medicine, Microbiology, and Epidemiology. He formerly served as Chief of Medicine and heads the Infectious Diseases Section at Harborview Medical Center; founded and directs the UW Center for AIDS and STD, a WHO Collaborating Center for AIDS and STD; and is Principal Investigator for the International Training & Education Center for Health (I-TECH), a collaboration between the UW and University of California, San Francisco, with programs in 30 countries. He served as President of IUSTI, co-founded the International Society for STD Research (ISSTDR), and is a member of the Institute of Medicine of the National Academy of Science. He has trained and/or mentored over 100 scientists. He has edited 30 books and manuscripts, and has published 700 research papers on infectious diseases, most concerning STDs.

Professor David Lewis 
Professor Lewis is Head of the Centre for HIV and Sexually Transmitted Infections at the National Institute for Communicable Diseases, a Division of the National Health Laboratory Service in Johannesburg, South Africa.  He holds honorary professorial appointments at the Universities of the Witwatersrand and Cape Town.  He has worked in the field of HIV/STIs since 1989, both as a clinician and a microbiologist.  His current work involves both HIV/STI research and surveillance in Southern Africa and his research interests focus on gonorrhoea, genital ulceration and men’s sexual health. He recently assisted with STI guideline revisions in South Africa, Namibia and for the Southern African Development Community (SADC).  In collaboration with the World Health Organisation, he led the development of the African Gonococcal Antimicrobial Susceptibility Programme (Afro-GASP) from 2010-2012.  Professor Lewis serves as an ISSTDR Board Member, IUSTI World President Elect, Regional Director for IUSTI-Africa, an Assistant Editor for Sexually Transmitted Infections and a Joint Editor for 'Sexual Health'.

Professor Tom Quinn
Tom Quinn MD, MSc is Senior Investigator and Head of the Section on International HIV/AIDS Research in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases.  He also serves as Associate Director for International Research for the Division of Intramural Research at NIAID. He is also Professor of Medicine and Pathology in the Johns Hopkins School of Medicine and has adjunct appointments in the Departments of International Health, Epidemiology, and Molecular Microbiology and Immunology in The Johns Hopkins School of Public Health.  In 2006 he was appointed Director of the Johns Hopkins Center for Global Health.

Dr. Quinn has been involved in HIV clinical and epidemiologic investigations in 25 countries, with current projects in Uganda, Zimbabwe, Tanzania, India, China, and Thailand. Among his professional activities, Dr. Quinn has been an Advisor/Consultant on HIV and STDs to the World Health Organization, Office of the Global AIDS Coordinator (PEPFAR), UNAIDS, and the U.S. Food and Drug Administration.   In 2004 he became a member of the Institute of Medicine of the National Academy of Science. In 2007 he was elected as fellow of the American Association for the Advancement of Science. He is also a fellow of the Infectious Disease Society of America and a member of the American Association of Physicians. He is an author of approximately 900 publications on HIV, STDs, and infectious diseases.


Dr Raj Patel
Dr Raj Patel, is a Consultant Physician specialising in Sexual Health and HIV medicine working within the  UK NHS.  He also holds a Senior Lecturer post at the University of Southampton.  He has developed a major research interest in  HSV infections and has held a number of key appointments within the UK  around the development , delivery and assessment of postgraduate specialist training.  

Professor Ian Frazer
Is the Chief Executive Officer (CEO) of the Translational Research Institute (TRI) in Brisbane, Australia. In his role as CEO, Professor Frazer is charged with leading the $354 million TRI to achieve its mission of being Australia’s first institute, and one of only a few in the world, to research, trial and manufacture breakthrough drugs in the one location, once construction is complete in 2012. The TRI will accommodate up to 650 researchers from the four TRI partners: The University of Queensland, Queensland University of Technology, Mater Medical Research Institute and the Princess Alexandra Hospital.

Internationally-renown for the co-creation of the technology for the cervical cancer vaccines, Professor Frazer began his career as a renal physician and clinical immunologist in Edinburgh, Scotland before emigrating in 1981 to Melbourne, Australia. He continued his clinical training and pursued studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay. In 1985, Professor Frazer accepted a teaching post with The University of Queensland and was appointed Director of The University of Queensland Diamantina Institute in 1991. In early 2011, Professor Frazer relinquished directorship of the Institute to commence in-post as CEO of the TRI. He retains an active research program at the Institute in immune responses to cancer.

Professor Frazer was awarded the 2005 CSIRO Eureka Prize for Leadership in Science and was selected as Queenslander of the Year, and Australian of the Year in 2006. He was also awarded the 2008 Prime Minister's Prize for Science, the 2008 Balzan Prize for Preventative Medicine, the 2009 Honda Prize and was recently elected as a Fellow of the esteemed Royal Society of London.